First Allied Advisory Services Inc. lessened its position in Humana Inc. (NYSE:HUM) by 5.9% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,014 shares of the insurance provider’s stock after selling 313 shares during the period. First Allied Advisory Services Inc.’s holdings in Humana were worth $1,185,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in HUM. BlackRock Inc. lifted its position in Humana by 2,281.7% in the 1st quarter. BlackRock Inc. now owns 12,387,144 shares of the insurance provider’s stock valued at $2,553,487,000 after purchasing an additional 11,867,056 shares during the last quarter. Vanguard Group Inc. boosted its stake in Humana by 1.6% during the 2nd quarter. Vanguard Group Inc. now owns 9,892,635 shares of the insurance provider’s stock valued at $2,380,366,000 after purchasing an additional 157,868 shares during the period. FMR LLC boosted its stake in Humana by 29.3% during the 2nd quarter. FMR LLC now owns 6,530,063 shares of the insurance provider’s stock valued at $1,571,264,000 after purchasing an additional 1,479,210 shares during the period. State Street Corp boosted its stake in Humana by 1.4% during the 1st quarter. State Street Corp now owns 6,274,811 shares of the insurance provider’s stock valued at $1,293,487,000 after purchasing an additional 84,716 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in Humana by 1.5% during the 2nd quarter. Renaissance Technologies LLC now owns 2,731,100 shares of the insurance provider’s stock valued at $657,157,000 after purchasing an additional 39,400 shares during the period. 95.12% of the stock is currently owned by institutional investors and hedge funds.

A number of equities research analysts have recently weighed in on HUM shares. ValuEngine raised Humana from a “hold” rating to a “buy” rating in a report on Friday, September 1st. UBS AG reissued a “neutral” rating and issued a $250.00 price objective (up from $237.00) on shares of Humana in a report on Wednesday, August 9th. BidaskClub raised Humana from a “sell” rating to a “hold” rating in a report on Thursday, August 10th. Cantor Fitzgerald reissued a “neutral” rating and issued a $223.00 price objective (up from $200.00) on shares of Humana in a report on Thursday, August 3rd. Finally, Morgan Stanley raised their target price on Humana from $269.00 to $276.00 and gave the company an “overweight” rating in a research report on Thursday, August 17th. One analyst has rated the stock with a sell rating, nine have given a hold rating and thirteen have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $246.60.

In other Humana news, CEO Bruce D. Broussard sold 12,000 shares of Humana stock in a transaction on Friday, August 11th. The shares were sold at an average price of $251.88, for a total transaction of $3,022,560.00. Following the completion of the sale, the chief executive officer now owns 80,086 shares of the company’s stock, valued at approximately $20,172,061.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider William Kevin Fleming sold 3,071 shares of the company’s stock in a transaction on Wednesday, August 23rd. The shares were sold at an average price of $250.98, for a total transaction of $770,759.58. Following the sale, the insider now owns 7,681 shares of the company’s stock, valued at approximately $1,927,777.38. The disclosure for this sale can be found here. Insiders have sold a total of 55,595 shares of company stock valued at $14,133,706 over the last three months. Company insiders own 0.80% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was originally published by Watch List News and is owned by of Watch List News. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://www.watchlistnews.com/first-allied-advisory-services-inc-sells-313-shares-of-humana-inc-hum/1603038.html.

Shares of Humana Inc. (NYSE HUM) traded up 0.39% during trading on Monday, hitting $244.58. The company had a trading volume of 70,202 shares. The stock has a market cap of $35.35 billion, a PE ratio of 20.12 and a beta of 0.86. The firm has a 50 day moving average of $250.95 and a 200 day moving average of $232.23. Humana Inc. has a 12-month low of $163.50 and a 12-month high of $259.76.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.08 by $0.41. The business had revenue of $13.53 billion for the quarter, compared to analysts’ expectations of $13.61 billion. Humana had a return on equity of 15.85% and a net margin of 3.37%. During the same quarter last year, the business earned $2.30 earnings per share. On average, analysts forecast that Humana Inc. will post $11.55 earnings per share for the current fiscal year.

The company also recently disclosed a dividend, which will be paid on Monday, October 16th. Shareholders of record on Friday, September 29th will be issued a dividend of $0.40 per share. The ex-dividend date is Thursday, September 28th. Humana’s dividend payout ratio is currently 13.06%.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.